Neurocrine Biosciences Appoints Samir Siddhanti as Chief Business Officer

Neurocrine Biosciences Inc. has appointed Samir Siddhanti as Chief Business Officer and a member of the company’s executive Management Committee.

As Chief Business Officer, Siddhanti will lead Neurocrine’s enterprise growth strategy, overseeing business development, corporate strategy, alliance management and program management to maximize the value of the company’s expanding pipeline through both internal innovation and strategic external opportunities.

“Throughout his tenure, Samir has become one of the company’s key leaders, helping shape Neurocrine’s long-term growth strategy through disciplined portfolio prioritization, thoughtful capital allocation and the execution of transformative business development initiatives,” said Kyle W. Gano, Ph.D., CEO, Neurocrine Biosciences. “As he steps into this expanded role, I look forward to his continued leadership as we advance our pipeline, pursue new opportunities and work to bring meaningful new therapies to patients with great needs.”

Experience

Since joining Neurocrine in 2017, Siddhanti has assumed leadership roles of increasing responsibility across business development, alliance management and corporate strategy. Most recently serving as Vice President, Business Development, he has led numerous strategic transactions and partnerships that have expanded Neurocrine’s pipeline and commercial portfolio, including the company’s recent acquisition of Soleno Therapeutics. He also serves as Program Team Leader for direclidine, providing strategic leadership for the program’s development in schizophrenia and bipolar disorder, while helping shape the company’s broader muscarinic portfolio strategy.

Prior to joining Neurocrine, Siddhanti was a member of the biotechnology equity research team at Goldman Sachs. He holds Bachelor of Science and Master of Science degrees in Management Science and Engineering from Stanford University.

“I’ve had the privilege of working alongside exceptional colleagues throughout my time at Neurocrine,” Siddhanti said, “and I’m honored by the opportunity to serve as Chief Business Officer.”